Oncolytics Biotech (TSE:ONC) has released an update.
Oncolytics Biotech Inc. announced the successful election of all eight director nominees at its Annual General Meeting, with shareholder approval of all proposed resolutions, including director appointments and auditor assignments. The clinical-stage biotech company, known for developing the immunotherapeutic agent pelareorep for various cancers, highlighted the continued advancement of this promising treatment towards registrational studies.
For further insights into TSE:ONC stock, check out TipRanks’ Stock Analysis page.
